Pitfalls in Reimbursement Decisions for Oncology Drugs in South Korea

Need for Addressing the Ethical Dimensions in Technology Assessment

Eun Cho, Euncheol Park, Myoung Sheen Kang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study aimed to discover to what extent ethical issues are considered in the reimbursement decision process based on health technology assessment (HTA) in Korea, especially for oncology medications. Public summary documents (PSDs) published by the Health Insurance Review and Assessment Service (HIRA) were analyzed for empirical and normative factors. For external comparison, PSDs presented by corresponding institutions of Australia and the United Kingdom were employed. Furthermore, the opinions of eight expert oncologists were obtained regarding the accountability of the evidence in PSDs. Among 7 oncology drugs, there were differences in the final decisions and empirical factors considered, such as selected comparators and interpretation of evidencebetween the PSDs from the three institutions. From an ethical viewpoint, the following matters were deficient in the HTA decision-making process for oncology drugs: clear and reasonable standards; identifying a nd evaluating ethical values; and public accountability for reasonableness about decisions and due process.

Original languageEnglish
Pages (from-to)3785-3792
Number of pages8
JournalAsian Pacific Journal of Cancer Prevention
Volume14
Issue number6
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Biomedical Technology Assessment
Republic of Korea
Social Responsibility
Civil Rights
Expert Testimony
Health Insurance
Korea
Ethics
Pharmaceutical Preparations
Decision Making
United Kingdom
Oncologists

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Cite this

@article{da74be27947f4ec2a8e36d4895bd3d1b,
title = "Pitfalls in Reimbursement Decisions for Oncology Drugs in South Korea: Need for Addressing the Ethical Dimensions in Technology Assessment",
abstract = "This study aimed to discover to what extent ethical issues are considered in the reimbursement decision process based on health technology assessment (HTA) in Korea, especially for oncology medications. Public summary documents (PSDs) published by the Health Insurance Review and Assessment Service (HIRA) were analyzed for empirical and normative factors. For external comparison, PSDs presented by corresponding institutions of Australia and the United Kingdom were employed. Furthermore, the opinions of eight expert oncologists were obtained regarding the accountability of the evidence in PSDs. Among 7 oncology drugs, there were differences in the final decisions and empirical factors considered, such as selected comparators and interpretation of evidencebetween the PSDs from the three institutions. From an ethical viewpoint, the following matters were deficient in the HTA decision-making process for oncology drugs: clear and reasonable standards; identifying a nd evaluating ethical values; and public accountability for reasonableness about decisions and due process.",
author = "Eun Cho and Euncheol Park and Kang, {Myoung Sheen}",
year = "2013",
month = "1",
day = "1",
doi = "10.7314/APJCP.2013.14.6.3785",
language = "English",
volume = "14",
pages = "3785--3792",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "6",

}

Pitfalls in Reimbursement Decisions for Oncology Drugs in South Korea : Need for Addressing the Ethical Dimensions in Technology Assessment. / Cho, Eun; Park, Euncheol; Kang, Myoung Sheen.

In: Asian Pacific Journal of Cancer Prevention, Vol. 14, No. 6, 01.01.2013, p. 3785-3792.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pitfalls in Reimbursement Decisions for Oncology Drugs in South Korea

T2 - Need for Addressing the Ethical Dimensions in Technology Assessment

AU - Cho, Eun

AU - Park, Euncheol

AU - Kang, Myoung Sheen

PY - 2013/1/1

Y1 - 2013/1/1

N2 - This study aimed to discover to what extent ethical issues are considered in the reimbursement decision process based on health technology assessment (HTA) in Korea, especially for oncology medications. Public summary documents (PSDs) published by the Health Insurance Review and Assessment Service (HIRA) were analyzed for empirical and normative factors. For external comparison, PSDs presented by corresponding institutions of Australia and the United Kingdom were employed. Furthermore, the opinions of eight expert oncologists were obtained regarding the accountability of the evidence in PSDs. Among 7 oncology drugs, there were differences in the final decisions and empirical factors considered, such as selected comparators and interpretation of evidencebetween the PSDs from the three institutions. From an ethical viewpoint, the following matters were deficient in the HTA decision-making process for oncology drugs: clear and reasonable standards; identifying a nd evaluating ethical values; and public accountability for reasonableness about decisions and due process.

AB - This study aimed to discover to what extent ethical issues are considered in the reimbursement decision process based on health technology assessment (HTA) in Korea, especially for oncology medications. Public summary documents (PSDs) published by the Health Insurance Review and Assessment Service (HIRA) were analyzed for empirical and normative factors. For external comparison, PSDs presented by corresponding institutions of Australia and the United Kingdom were employed. Furthermore, the opinions of eight expert oncologists were obtained regarding the accountability of the evidence in PSDs. Among 7 oncology drugs, there were differences in the final decisions and empirical factors considered, such as selected comparators and interpretation of evidencebetween the PSDs from the three institutions. From an ethical viewpoint, the following matters were deficient in the HTA decision-making process for oncology drugs: clear and reasonable standards; identifying a nd evaluating ethical values; and public accountability for reasonableness about decisions and due process.

UR - http://www.scopus.com/inward/record.url?scp=84882725017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882725017&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2013.14.6.3785

DO - 10.7314/APJCP.2013.14.6.3785

M3 - Article

VL - 14

SP - 3785

EP - 3792

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 6

ER -